MX2019011702A - Ensayos de inmunogenicidad mejorados. - Google Patents

Ensayos de inmunogenicidad mejorados.

Info

Publication number
MX2019011702A
MX2019011702A MX2019011702A MX2019011702A MX2019011702A MX 2019011702 A MX2019011702 A MX 2019011702A MX 2019011702 A MX2019011702 A MX 2019011702A MX 2019011702 A MX2019011702 A MX 2019011702A MX 2019011702 A MX2019011702 A MX 2019011702A
Authority
MX
Mexico
Prior art keywords
improved immunogenicity
immunogenicity assays
neutralizing anti
drug antibodies
relates
Prior art date
Application number
MX2019011702A
Other languages
English (en)
Inventor
Boutton Carlo
Snoeck Veerle
Coddens Annelies
Ange Buyse Marie-
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2019011702A publication Critical patent/MX2019011702A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

La presente invención se refiere a ensayos de inmunogenicidad mejorados y a métodos para realizarlos. En particular, la presente invención se refiere a ensayos de inmunogenicidad mejorados que son capaces de distinguir los anticuerpos antidrogas neutralizantes de los anticuerpos antidrogas no neutralizantes. Más en particular, la presente invención se refiere a ensayos de inmunogenicidad mejorados que permiten (cantidades o concentraciones de) anticuerpos antidrogas neutralizantes, para ser detectados o medidos en una muestra, incluso en presencia de anticuerpos antidrogas no neutralizantes.
MX2019011702A 2017-03-31 2018-03-29 Ensayos de inmunogenicidad mejorados. MX2019011702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479496P 2017-03-31 2017-03-31
PCT/EP2018/058232 WO2018178307A1 (en) 2017-03-31 2018-03-29 Improved immunogenicity assays

Publications (1)

Publication Number Publication Date
MX2019011702A true MX2019011702A (es) 2019-11-01

Family

ID=61827757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011702A MX2019011702A (es) 2017-03-31 2018-03-29 Ensayos de inmunogenicidad mejorados.

Country Status (7)

Country Link
US (1) US12480957B2 (es)
EP (1) EP3602056A1 (es)
CN (1) CN110546506B (es)
AU (1) AU2018241286B2 (es)
MX (1) MX2019011702A (es)
SG (1) SG11201908154RA (es)
WO (1) WO2018178307A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021136773A1 (en) 2020-01-02 2021-07-08 F. Hoffmann-La Roche Ag Ada-response specification assay
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2024007473A (es) 2021-12-14 2024-09-10 Cdr Life Ag Activador del linfocito t dirigido al mhc doble.
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
WO2025210181A1 (en) 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
US20250388688A1 (en) 2024-04-04 2025-12-25 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof
WO2025215160A1 (en) 2024-04-11 2025-10-16 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted prame peptide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
EA200801166A1 (ru) 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN101506659B (zh) * 2006-09-12 2012-12-12 弗·哈夫曼-拉罗切有限公司 抗药物抗体测定法
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
EP2285833B1 (en) * 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
US11009511B2 (en) * 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies

Also Published As

Publication number Publication date
AU2018241286A1 (en) 2019-09-26
CN110546506A (zh) 2019-12-06
US20210239709A1 (en) 2021-08-05
US12480957B2 (en) 2025-11-25
CN110546506B (zh) 2023-04-04
US20220099682A9 (en) 2022-03-31
CA3056727A1 (en) 2018-10-04
EP3602056A1 (en) 2020-02-05
SG11201908154RA (en) 2019-10-30
AU2018241286B2 (en) 2025-03-13
WO2018178307A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
MX2019011702A (es) Ensayos de inmunogenicidad mejorados.
IL265396A (en) Methods and compositions for detecting analytes
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
PH12017501967A1 (en) Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof
MY172330A (en) Cancer detection method using sense of smell of nematodes
WO2015114506A3 (en) Biosensors for the detection of infection and associated maladies
PL3523639T3 (pl) Odczynniki wykrywające i układy elektrod do elementów diagnostycznych testów wieloanalitowych oraz sposoby ich zastosowania
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MY183551A (en) Method for measuring reactivity of fviii
ZA202003408B (en) A microcapsule for detecting and/or quantitating an analyte in a sample
EP4465017A3 (en) System for determining the amount of hemoglobin in a plasma fraction
WO2016023991A8 (de) Verfahren zur mikrobiom-analyse
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
WO2016209773A9 (en) Improved assays and methods for allergen detection
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
MX2017001134A (es) Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana.
EP3593122A4 (en) METHOD OF DETECTION OF ANALYTES
SG10201901836PA (en) Test strip assembly
MX2016017136A (es) Composiciones y metodos para detectar pegivirus 2 de humano (hpgv-2).
PH12018502286A1 (en) Rt-pcr-hrm or pcr-hrm primer, reagent and method for rapidly distinguishing four serotypes of dengue virus
MY189736A (en) Methods for detecting pathogenicity of ganoderma sp.
EP4400600A3 (en) Methods for detecting multiple nucleic acids in a sample